Ibex Selected by Kantonsspital Baselland to Deliver the First AI-powered Cancer Diagnostics Solution in Switzerland

Advertisement

Kantonsspital Baselland to deploy Galen™ AI-powered platform, to help pathologists improve accuracy and efficiency during initial cancer diagnosis

Tel Aviv, Israel And Basel, SwitzerlandAnd November 3, 2021 /PRNewswire/- ibex medical analysis, the pioneer in AI-assisted cancer diagnosis and Baseland Cantonal Hospital, a healthcare provider in Northwest SwitzerlandAnd Today I announced the first publication in Switzerland An AI solution that supports pathologists during routine cancer diagnosis.

Ibex selected by Kantonsspital Baselland to deliver the first AI-powered cancer diagnosis solution in Switzerland

Pathologists play a critical role in disease detection and diagnosis, with their evaluations considered vital to arriving at the correct treatment decisions by oncologists. However, the rise in the prevalence of cancer and advances in personalized medicine have increased diagnostic complexity, greatly increasing the workload of pathologists. As pathology labs move toward digital solutions, pathologists can implement AI-enhanced workflows to improve the quality and efficiency of cancer diagnoses, leading to better patient care.

Advertisement

Ibex is transforming cancer diagnosis by harnessing artificial intelligence and machine learning technology on an unprecedented scale. Ibex’s Galen platform helps pathologists improve the quality of cancer diagnosis, reduce diagnostic time and increase productivity1, and implement real-time quality control2. CE Certified for Breast and Prostate Cancer Detection in Multiple Courses of Action and recently awarded Breakthrough device design by the US Food and Drug Administration (FDA). Galen has already shown outstanding results in clinical studies3,4 It is published in laboratories around the world where it is used as part of daily clinical practice.

Kantonsspital Baselland (KSBL) is a hospital that provides molecular and histological integrative cancer diagnostics and personalized oncological care. KSBL has digitized its pathology services with Philips’ IntelliSite pathology solution, deploying a network of high-quality digital scanners, as well as an image management solution and an in-house developed lab information system. As part of the AI ​​deployment, KSBL pathologists will use the Galen platform, enabling them to streamline workflows and improve accuracy during initial diagnosis by automatically prioritizing case, cancer-specific heat maps, grading and other productivity-improving tools.

Advertisement

“Timely and highest quality diagnosis is the cornerstone of cancer care at Kantonsspital Bselland, and we are committed to continually improving technology and processes in our laboratory,” he said. Kirsten Mertz MD, professor of pathology at KSBL. “We were a pioneer in embracing digital pathology in Switzerland We are particularly proud of being the first hospital in the country to implement AI in pathology. We have been impressed by the performance demonstrated by Ibex’s AI technology across several clinical studies in Europe And United State We look forward to getting hands-on experience working with their solution and examining how it can help improve patient care.”

“We are pleased to collaborate with Kantonsspital Baselland and enable their pathologists to use the latest AI-powered solutions to more accurately detect cancer and improve the quality and efficiency of diagnosis,” he said. Stuart Shand, Chief Commercial Officer, Ibex Medical Analytics. “Through this collaboration, KSBL is setting a new standard in the quality of cancer care, proving its leadership and commitment to its patients by deploying an advanced clinical-grade AI solution to ensure the best possible outcomes. AI and digital pathology technologies have become an essential part of cancer care programs , and its accreditation is a shared vision of KSBL and Ibex.”

About Baseland Cantonal Hospital

Kantonsspital Baselland (KSBL) is a hospital in Northwest Switzerland With 3,300 employees providing care to several thousand oncology patients each year. Of these, approximately 150 patients are diagnosed with prostate cancer each year. The Cantonal Institute of Pathology is the Department of Pathology at KSBL and offers a cutting-edge histological and molecular cancer diagnostic service.

About IBEX Medical Analytics

Ibex is a leader in AI-assisted cancer diagnosis in pathology. We enable clinicians to provide every patient with an accurate, personalized and timely cancer diagnosis by developing clinical-grade AI algorithms and digital workflows that aid in the detection and classification of cancer in biopsies. Our Galen™ platform is the first integrated pathology AI-powered diagnostic solution used in routine clinical practice worldwide, supporting pathologists and service providers in improving the quality and accuracy of diagnoses, implementing comprehensive quality control, reducing delivery times, and increasing productivity from during a more efficient workflow. Ibex’s AI technology is built on deep learning algorithms trained by a team of pathologists, data scientists, and software engineers. For more information, go to www.ibex-ai.com.

Media contact
Yael Hart
GK Caribou
yael@gkpr.com

[1] Raoux D et al., New AI-based solution to support initial prostate cancer diagnosis increases accuracy and efficiency of reporting in clinical routine. USCAP 2021: https://www.youtube.com/watch?v=9XuWK8PmUlw

[2] Sandbank J et al, Deployment of an AI-based multi-tissue quality control system in routine clinical workflow. European Pathology Congress 2020: https://ibex-ai.com/wp-content/uploads/2021/03/Maccabi-IBEX-ECP2020-poster.pdf

[3] Digital Health LANCET, August 2020Pantanowitz et al., An artificial intelligence algorithm for diagnosing prostate cancer in whole slide images of core needle biopsies: a clinical validation and publication study. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30159-X/fulltext

[4] Laifenfeld D et al, An AI-based solution to cancer diagnosis in primary prostate needle biopsies: a prospective, multi-site clinical study. USCAP 2021: https://www.youtube.com/watch?v=9nDiJY90v9c

Photo – https://mma.prnewswire.com/media/1677260/Ibex_KSBL.jpg

Advertisement

Leave a reply:

Your email address will not be published.

Site Footer

Sliding Sidebar